Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
The WisdomTree BioRevolution Fund (WDNA) is focused on investing in companies that are leveraging biotechnology and genomics to drive innovation in healthcare and agriculture. The fund targets firms involved in gene editing, synthetic biology, and personalized medicine, primarily in North America and Europe, capitalizing on the growing demand for advanced biotechnological solutions.
WDNA generates revenue through management fees based on the total assets under management, which are derived from investments in biotechnology and genomics companies. The fund's competitive advantage lies in its specialized focus on high-growth sectors, allowing it to attract investors seeking exposure to cutting-edge technologies.
Performance of biotech and genomics stocks in the fund's portfolio
Changes in investor sentiment towards healthcare innovation
Regulatory developments impacting biotechnology investments
Market trends in healthcare spending and R&D investments
Technological disruption in biotechnology that could render current investments obsolete
Regulatory changes that could impact the profitability of biotech firms
Increased competition from other specialized biotech funds
Market volatility affecting investor appetite for biotech investments
Liquidity risk associated with potential redemptions during market downturns
Operational risk from reliance on third-party service providers
moderate - The fund's performance is linked to overall economic conditions that affect healthcare spending and investment in biotechnology.
Rising interest rates can lead to higher financing costs for biotech companies, potentially impacting their growth and, in turn, the fund's performance. However, the fund's focus on innovative sectors may mitigate some of this sensitivity.
minimal - The fund does not have significant credit exposure as it primarily invests in equities.
growth - Investors seeking exposure to high-growth sectors such as biotechnology and genomics.
high - The fund's focus on emerging technologies typically results in higher volatility.
